Ensifentrine for Preventing COPD Exacerbations

Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

Recruiting Phase 3 Interventional Study
Pulmonary Disease, Chronic Obstructive
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 80
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
2,136 (estimated)
Sponsor
Merck Sharp & Dohme LLC · Industry
Who this trial is looking for

This trial is looking for adults with Chronic Obstructive Pulmonary Disease (COPD) who have had episodes of worsening symptoms. Participants will take a study drug called ensifentrine or a placebo for prevention of these episodes while continuing their regular treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with COPD for more than 12 months
  • I've been stable on my current COPD treatment for at least 2 months
  • I have had at least one moderate or severe COPD exacerbation in the past year
  • I am a current or former smoker with a history of smoking
  • My lung function test shows FEV1 between 25% and 70% of normal

You may not be able to join if

  • I have been intubated for respiratory failure in the past year
  • I am on long-term oxygen therapy for more than 15 hours a day
  • I use bilevel positive airway pressure for a respiratory condition not related to sleep apnea
  • I have used biologic therapy in the past 6 months
  • I have a history of cancer in the past 5 years, except for certain skin cancers

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of l…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Inclusion Criteria include but are not limited to: * Has a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) that was made ≥12 months prior to randomization * Has been on the stable treatment with the same standard of care (SOC) with long-acting muscarinic antagonist (L…
Contacts

Toll Free Number

1-888-577-8839

Trialsites@msd.com

CONTACT